Coloplast delivers on ambitious targets with solid interim report

Coloplast delivered revenue of DKK 9,214 million and 9% organic growth in the first nine months of the 2013/14 financial year. Q3 organic growth was 8%.

EBIT before special items increased by 13% to DKK 3,047 million. The EBIT margin before special items was 33%, against 31% in 9M 2012/13.

Delivering on ambitious targets

“I'm pleased with the solid financial results we are announcing today. We are continuing our string of healthy growth in all business areas and in all regions, and our consolidated profit is matching the high expectations we have for our company,” said Coloplast CEO Lars Rasmussen.

Sales growth by business area was as follows: Ostomy Care 8%, Continence Care 11%, Urology Care 10% and Wound & Skin Care 10%. Coloplast grew its European business by 6%, Other Developed Markets by 10% and Emerging Markets by 24%.

“I'm particularly pleased with the sales performance in our Continence Care, Urology Care and Wound & Skin Care businesses, which all delivered double-digit growth rates,” said Lars Rasmussen, and he continued: “I'm also encouraged by our sales growth in Other Developed Markets, which was driven by the powerful sales performance in the USA of our continence care and ostomy care products, and our sales growth in Emerging Markets based especially on our positive performance in China, Brazil and Argentina."

Financial guidance for 2013/14 unchanged

Following the Q3 interim report, Coloplast continues to expect full-year organic revenue growth of about 9% and of about 7% in DKK. The company continues to expect the EBIT-margin before special items to be 33-34% at constant exchange rates and about 33% in DKK.

The Q3 Interim Report.